Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03683498
What this trial is testing

Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease

Who this might be right for
Chronic Graft vs Host Disease
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 16
Testing effectiveness (Phase 2)Looking for participantsNCT05745714
What this trial is testing

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology
Large-scale testing (Phase 3)Study completedNCT05755438
What this trial is testing

Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Who this might be right for
Prurigo
Incyte Corporation 204
Large-scale testing (Phase 3)Study completedNCT03745638
What this trial is testing

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 631
Testing effectiveness (Phase 2)Study completedNCT03616184
What this trial is testing

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Who this might be right for
Graft-versus-host-disease (GVHD)
University of Nebraska 49
Very early researchLooking for participantsNCT06008275
What this trial is testing

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Who this might be right for
Metastatic Triple-Negative Breast CarcinomaBreast Cancer
Baylor Research Institute 20
Large-scale testing (Phase 3)Study completedNCT02292446
What this trial is testing

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals 161
Early research (Phase 1)Study completedNCT02145637
What this trial is testing

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC
Yonsei University 30
Early research (Phase 1)Study completedNCT06213831
What this trial is testing

Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Who this might be right for
Prurigo Nodularis
Incyte Corporation 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06075225
What this trial is testing

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Who this might be right for
GVHDAcute Stem Cell Transplant Complications
Sichuan University 62
Testing effectiveness (Phase 2)Study completedNCT03491215
What this trial is testing

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Who this might be right for
Acute Graft Versus Host Disease
Novartis Pharmaceuticals 45
Early research (Phase 1)Not Yet RecruitingNCT07521046
What this trial is testing

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Who this might be right for
Myelofibrosis
University of Utah 15
Large-scale testing (Phase 3)Ended earlyNCT02962388
What this trial is testing

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Who this might be right for
Essential Thrombocythemia
French Innovative Leukemia Organisation 13
Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Testing effectiveness (Phase 2)Study completedNCT05872477
What this trial is testing

Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

Who this might be right for
Vitiligo
Centre Hospitalier Universitaire de Nice 20
Early research (Phase 1)Study completedNCT06673654
What this trial is testing

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Who this might be right for
Atopic Dermatitis
Sun Pharmaceutical Industries, Inc. 476
Large-scale testing (Phase 3)Active Not RecruitingNCT04769895
What this trial is testing

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Who this might be right for
Acute Graft Versus Host Disease in IntestineSteroid Refractory GVHD
MaaT Pharma 66
Testing effectiveness (Phase 2)Ended earlyNCT02072057
What this trial is testing

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Who this might be right for
Cancer Cachexia
Kantonsspital Aarau 8
Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Testing effectiveness (Phase 2)Looking for participantsNCT07238712
What this trial is testing

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Who this might be right for
Acute Myeloid Leukemia (AML)Chronic Myeloid LeukemiaMyelodysplastic Syndromes (MDS)+2 more
St. Petersburg State Pavlov Medical University 60
Next Page
26